Literature DB >> 20167031

Health care services provided during physician office visits for hypertension: differences by specialty.

Jing Fang1, Nora L Keenan, Carma Ayala.   

Abstract

The changing health care system has reduced patients' access to specialty care. Often, patients with hypertension visit noncardiologists. The objective of this study is to compare differences by physician specialty in the provision of health care services during office visits for hypertension. The authors examined office visits for US physicians by using data from the National Ambulatory Medical Care Survey for 2003 to 2005. Of more than 274 million hypertension visits, 35.5%, 43.9%, 8.5%, and 12.1% visits were made to general practitioners/family physicians, internists, cardiologists, and other specialties, respectively. Visitors to cardiologists were more likely to have coronary heart disease and heart failure than visitors to other physicians. While prescriptions for antihypertensive drugs overall were similar by specialty, cardiologists were more likely to prescribe lipid-lowering drugs (odds ratio [OR], 1.60; 95% confidence interval [CI], 1.14-2.24) and aspirin (OR, 2.76; 95% CI, 1.81-4.20), calcium channel blockers (OR, 1.48; 95% CI, 1.12-1.96), beta-blockers (OR, 1.83; 95% CI, 1.35-2.48), and alpha-blockers (OR, 2.10; 95% CI, 1.46-2.95) than general practitioners/family physicians after adjusting for relevant risk factors. There was no difference by specialty in providing/making a referral for nutrition/exercise counseling among physicians. Among hypertension office visits in the United States, cardiologists were more likely to provide lipid-lowering drugs, aspirin, calcium channel blocker, beta-blockers, and alpha-blockers than other physicians.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167031      PMCID: PMC8673341          DOI: 10.1111/j.1751-7176.2009.00219.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  23 in total

1.  Evidence-based guidelines for cardiovascular disease prevention in women.

Authors:  Lori Mosca; Lawrence J Appel; Emelia J Benjamin; Kathy Berra; Nisha Chandra-Strobos; Rosalind P Fabunmi; Deborah Grady; Constance K Haan; Sharonne N Hayes; Debra R Judelson; Nora L Keenan; Patrick McBride; Suzanne Oparil; Pamela Ouyang; Mehmet C Oz; Michael E Mendelsohn; Richard C Pasternak; Vivian W Pinn; Rose Marie Robertson; Karin Schenck-Gustafsson; Cathy A Sila; Sidney C Smith; George Sopko; Anne L Taylor; Brian W Walsh; Nanette K Wenger; Christine L Williams
Journal:  Circulation       Date:  2004-02-04       Impact factor: 29.690

2.  Specialty differences in cardiovascular disease prevention practices.

Authors:  R S Stafford; D Blumenthal
Journal:  J Am Coll Cardiol       Date:  1998-11       Impact factor: 24.094

3.  Physician specialty and quality of care for CHF: different patients or different patterns of practice?

Authors:  Jonathan G Howlett; Jafna L Cox; Haissam Haddad; Jennie Stanley; Michael McDonald; David E Johnstone
Journal:  Can J Cardiol       Date:  2003-03-31       Impact factor: 5.223

4.  Physician specialty and mortality among elderly patients hospitalized with heart failure.

Authors:  JoAnne Micale Foody; Saif S Rathore; Yongfei Wang; Jeph Herrin; Frederick A Masoudi; Edward P Havranek; Harlan M Krumholz
Journal:  Am J Med       Date:  2005-10       Impact factor: 4.965

5.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

6.  Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines.

Authors:  M E Edep; N B Shah; I M Tateo; B M Massie
Journal:  J Am Coll Cardiol       Date:  1997-08       Impact factor: 24.094

7.  Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004.

Authors:  Jeffrey A Cutler; Paul D Sorlie; Michael Wolz; Thomas Thom; Larry E Fields; Edward J Roccella
Journal:  Hypertension       Date:  2008-10-13       Impact factor: 10.190

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.

Authors:  Randall S Stafford; Curt D Furberg; Stan N Finkelstein; Iain M Cockburn; Tseday Alehegn; Jun Ma
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more
  2 in total

1.  Hypertension-associated hospitalizations and costs in the United States, 1979-2006.

Authors:  Guijing Wang; Jing Fang; Carma Ayala
Journal:  Blood Press       Date:  2013-07-25       Impact factor: 2.835

Review 2.  How well do we care for patients with hypertension?

Authors:  Michael A Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-11       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.